Published Use of new drugs in Canada!

I wish I didn't do this survey. If this leads to any more chemicals being banned here in Canada I want no part of it. What S.J.P. said has kind of made me worried.

Thanks for contributing. Of course this is a legitimate fear. But I would note one thing - it is highly unlikely that a survey like this will unearth an entirely new NPS that governments are not already monitoring. Globally there are over 700 NPS being monitored at the moment. Indeed because this survey is recruiting Bluelighters, we might find a bias towards the use of certain classes of NPS, and possibly (this is a guess) we might find more harm reduction practices and less harm among these examples. Governments are looking for information about whether there is a new drug that is specifically causing problems. But they will find that out through the existing online and other monitoring information (yes even the text of our posts at BL) in addition to surveys like this one.
 
Hi all, I've answered a few unanswered posts above and am happy to discuss these issues anytime.
This survey has now closed.
We look forward to finding out the results in due course.
Thanks to everyone who has supported the project.
 
Some of this information will end up in the hands of Canadian Emergency Room physicians who will IMMEDIATELY know how to treat an anxiolytic overdose of a Canadian teenager because the novel benzodiazepine analogue the kid is on won't trigger a positive on today's screens for any drug use whatsoever.

We Canadian's are actually proud of our elected officials, not blindly, but because we the people are politically aware and invested enough in the actual process of democracy that we intelligently elected a few that might actually care about some teenager 6 years from now as opposed to focusing on maximizing revenue through A War On Drugs....ad infinituum
 
Hi everyone - please see below results update from this 2017 study.

Thank you for your interest and participation in this survey!

The purpose of this survey is to observe patterns of use of new psychoactive substances, as voiced directly from people with lived and living experience. The following results have been provided by Health Canada based on the 2017 pilot survey data. Updated findings from the current survey will be posted as they become available.

In late 2017, Health Canada launched a pilot survey on Bluelight about new psychoactive substance (NPS) use experiences. During that time, 134 respondents from the Bluelight community completed the survey, resulting in a number of reported substances including, but not limited to: 1P-LSD, 25I-NBOMe, 2C-T-7, 4-AcO-DET, 4F-MPH, and ALD-52. On average, 53% of people who reported an episode of NPS use said that it was not their first time using that particular substance, and 79% indicated that they had taken the substance at least three times in the past 12 months.

The majority of reported substances came in the form of a powder (44% ) or blotter/film/stamp (27% ), and was most often taken through absorption (28% ) or swallowed as a pill/capsule (16% ). Most respondents (74% ) reported taking a single dose of the substance, with few respondents indicating that they either took a larger dose than intended (23% ) or took more doses than intended (13% ).

Respondents reported that they took the substance in order to achieve a variety of desired effects, with the most common being hallucination (i.e., to alter one’s visual or auditory perceptions; 41% ), to alter one’s consciousness (24% ), or to reduce or manage anxiety, fear, stress or depression (22% ), and 80% indicated that the desired effects were achieved. Although most respondents felt that the substance they took was of high purity (86% ), one quarter (25% ) of respondents reported at least one negative health effect, with the most common being dizziness or balance problems (25% ), involuntary body movements (22% ), psychological crisis involving depression, anxiety, psychosis, paranoia, or a manic episode (18% ), hyperthermia (20% ), irregular or fast heart beats, severe arrhythmia or tachycardia (17% ), and nausea and vomiting (17% ).

Overall, the majority of respondents reported taking any NPS monthly or less (79% ) and 61% indicated that they plan to use NPS sometime in the future.

For help with problematic substance use, please visit: https://www.canada.ca/en/health-can...-help/get-help-problematic-substance-use.html
 
Hi all,
Here is the French version of the 2017 study results (same as those posted above in English by Tronica):

Les résultats ci-dessous ont été fournis par Santé Canada à l’aide des données de l’enquête pilote de 2017. Les résultats actualisés de l’enquête actuelle seront publiés dès qu’ils seront disponibles.

À la fin de 2017, Santé Canada a lancé une enquête pilote sur Bluelight concernant les expériences de consommation de nouvelles substances psychoactives. Au cours de cette période, 134 personnes de la communauté Bluelight ont répondu à l’enquête, ce qui a donné lieu à la déclaration d’un certain nombre de substances, notamment, mais pas exclusivement : 1P-LSD, 25I-NBOMe, 2C-T-7, 4-AcO-DET, 4F-MPH et ALD-52. En moyenne, 53 % des personnes ayant déclaré un épisode de consommation ont mentionné que ce n’était pas la première fois qu’elles consommaient cette substance particulière, et 79 % ont indiqué qu’elles avaient pris cette substance au moins trois fois au cours des 12 derniers mois.
La majorité des substances déclarées se présentaient sous forme de poudre (44 % ) ou de buvard, film ou timbre (27 % ), et étaient le plus souvent prises par absorption (28 % ) ou avalées sous forme de pilule ou capsule (16 % ). La plupart des répondants (74 % ) ont déclaré avoir pris une seule dose de la substance, et peu de répondants ont indiqué avoir pris une dose plus importante que prévu (23 % ) ou avoir pris plus de doses que prévu (13 % ).
Les répondants ont indiqué qu’ils prenaient la substance pour obtenir divers effets, les plus courants étant les hallucinations (c.-à-d. pour modifier leurs perceptions visuelles ou auditives (41 % ), pour modifier leur conscience (24 % ), ou pour réduire ou gérer l’anxiété, la peur, le stress ou la dépression (22 % ), et 80 % ont indiqué que les effets souhaités étaient obtenus. Bien que la plupart des répondants aient estimé que la substance qu’ils ont prise était de grande pureté (86 % ), un quart (25 % ) des répondants ont signalé au moins un effet négatif sur la santé, les plus fréquents étant les étourdissements ou les problèmes d’équilibre (25 % ), les mouvements corporels involontaires (22 % ), les crises psychologiques telles que la dépression, l’anxiété, la psychose, la paranoïa ou un épisode maniaque (18 % ), l’hyperthermie (20 % ), les battements de cœur irréguliers ou rapides, l’arythmie grave ou la tachycardie (17 % ), et les nausées et vomissements (17 % ).
Dans l’ensemble, la majorité des répondants ont déclaré prendre des nouvelles substances psychoactives tous les mois ou moins (79 % ) et 61 % ont indiqué qu’elles prévoyaient utiliser de telles substances dans l’avenir.

Pour obtenir de l’aide en cas de consommation problématique de substances, veuillez consulter le site Web à https://www.canada.ca/fr/sante-canada/services/dependance-aux-drogues/obtenir-aide/obtenir-aide-consommation-problematique-substances.html.


If anyone has any questions, feel free to post here or message us directly at [email protected].
Thanks!
 
Top